The IPO provides BlossomHill with substantial near-term funding to advance its pipeline. Monitor first-day trading and the exercise of the underwriters' overallotment option — a strong debut and full exercise would signal robust demand and add ~$22.5M in proceeds. Key catalysts to watch are clinical readouts for BH-30643 and BH-30236.
Price Chart
Executive Summary
BlossomHill Therapeutics priced its upsized IPO of 9,375,000 shares at $16.00/share, raising $150.0 million in gross proceeds. The shares will begin trading on Nasdaq on August 7, 2026, under the ticker BLSM. The offering provides capital to advance its clinical-stage oncology pipeline.
Key Financial Metrics
Key Facts
- BlossomHill Therapeutics priced an upsized IPO of 9,375,000 shares at $16.00 per share
- Gross proceeds of $150.0 million from the IPO (before expenses)
- Underwriters have a 30-day option for an additional 1,406,250 shares at the same price
- Shares expected to start trading on The Nasdaq Global Select Market on August 7, 2026, under ticker BLSM
- Lead book-running managers: J.P. Morgan, Leerink Partners, and Guggenheim Securities
- Lead programs: BH-30643 (EGFR inhibitor for NSCLC) and BH-30236 (CLK inhibitor for AML/HR-MDS)
Financial Impact
$150.0 million gross proceeds from IPO (before underwriting discounts and commissions)
Risk Factors
- Clinical-stage biotech with no approved products; pipeline may fail in trials
- Share dilution from IPO and potential overallotment option
- Competition from established EGFR and CLK inhibitors
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340894 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $14.63 (+31.44%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $14.63 (+43.16%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $14.63 (−43.16%) |
Sep 15, 2026 5w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $14.63 (−34.01%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $14.63 (−10.52%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $14.63 (−11.44%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $14.63 (−11.44%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $14.63 (−8.51%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $14.63 (−8.56%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $14.63 (−8.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers